期刊文献+

盐酸万古霉素和去甲万古霉素用药分析

ANALYSIS OF DRUG USE OF VANCOMYCIN HYDROCHLORIDE AND NORVANCOMYCIN
下载PDF
导出
摘要 [目的]了解我院临床万古霉素类药物的使用情况,评价其用药合理性。[方法]采用回顾性调查方法,分别将2007年1~5月我院住院病人应用万古霉素类药物—去甲万古霉素(华北制药)、万古霉素(稳可信)的病例共64份进行药物合理性利用分析。[结果]64份病例中合理用药10例(15.625%),基本合理用药6例(9.375%),不合理用药48例(75%)。[结论]目前万古霉素类药物的临床应用有所放宽,不合理用药也随之增加。提高合理用药水平有助于减少耐药菌株的出现,应采取措施,严格适应证,保护该类药物的使用寿命。 [ Objective ] To investigate the clinical utilization status of vaneomycin in our hospital, and to evaluate the rationality of drug use. [ Methods] By retrospective survey method, 64 patients treated by vaneomycin - norvancomycin (North China Pharmaceutical) and vancomycin (stable credible) in our hospital from January 2007 to May 2007 were collected to analyze the rational utilization of drug. [Results] Out of 64 patients, 10 patients with rational utilization of drug, 6 patients with basic rational utilization of drug and 48 patients with non-rational utilization of drug accounted for 15.625%, 9.375% and 75%, respectively. [ Conclusion] With the liberalization of clinical utilization of vancomycin, the non-rational utilization of drug is increasing. To improve the rational use of drug could be helpful to decrease the drug resistant strain, and effective measures should be taken to strengthen the indication so as to protect the useful life of vancomvcin.
作者 王喆
出处 《现代预防医学》 CAS 北大核心 2008年第8期1590-1591,共2页 Modern Preventive Medicine
关键词 去甲万古霉素 万古霉素 合理用药 Norvancomycin Vancomycin Rational use of drug
  • 相关文献

参考文献2

二级参考文献27

  • 1[1]Hirnatsu K, Hanaki H, Iro T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. [J]. J Antimicrob Chemother,1997,40(1): 135
  • 2[2]
  • 3[3]Sieradzko K, Villari P, Tomasz A. Decreased susceptibilities to teicomycin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of Staphylococci.[J]. Antimicrob Agents Chemother, 1998, 42(1): 100
  • 4[4]Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis, [J]. Antimicrob Agents Chemother, 1997, 41(1):24
  • 5[5]Ligozzi M, Cascio GL, Fontana R. vanA gene cluster in a vancomycin-resistant clinical isolate of Bacillus circulans.[J]. Antimicrob Agents Chemother, 1998, 42(8): 2055
  • 6[6]Parenti F, Cavalleri. Novel glycopeptide antibiotics of the dalbaheptide group. [J]. Drug Fut, 1990, 15(1): 57
  • 7[7]Yan,H-S, Qi D-F, Cheng X-H,et al. Antibiotic activities and affinityes for bacterial cell wall analogue of Ndemethylvancomycin and its derivaties. [J]. J Antibiotics,1998,51(8):750
  • 8[8]Allen NE, LeTourneau D, Hobbs JN. The role of hydrophobic chain as antibacterial activity of semisynthetic glycopeptide antibiotics. [J]. J Antibiotics, 1997, 50(8):675
  • 9[9]Pavlov AY, Berdnikova TF, Olsufyeva EN, et al.Caoboxamides and hydrazide of glycopeptide antibiotic eremomycin synthesis and antibacterial activity. [J]. J Antibiotics, 1996, 49(2): 194
  • 10[10]Linsdell H, Toiron C, Bruix M, et al. Dimerization of A82846B,vancomycin and ristocetin: influence on antibiotic complexation with cell wall model peptides. [J]. J Antibiotics, 1996, 49(2): 181

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部